Management of Coronary Artery Spasm
Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standa...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2023-05-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2022.47 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849220226118320128 |
|---|---|
| author | Gaetano Antonio Lanza Hiroaki Shimokawa |
| author_facet | Gaetano Antonio Lanza Hiroaki Shimokawa |
| author_sort | Gaetano Antonio Lanza |
| collection | DOAJ |
| description | Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standard treatments, several other alternative drugs and interventions have been proposed, including the Rho-kinase inhibitor fasudil, anti-adrenergic drugs, neural therapies and percutaneous coronary interventions. In patients with syncope or cardiac arrest caused by CAS-related tachyarrhythmias, or even bradyarrhythmias, implantation of an ICD or pacemaker, respectively, should be considered according to the risk of recurrence and efficacy of vasodilator therapy. |
| format | Article |
| id | doaj-art-17d1c3919fb441b4928f8e16643ece5a |
| institution | Kabale University |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2023-05-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-17d1c3919fb441b4928f8e16643ece5a2024-12-14T16:04:26ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642023-05-011810.15420/ecr.2022.47Management of Coronary Artery SpasmGaetano Antonio Lanza0Hiroaki Shimokawa1Fondazione Policlinico A Gemelli IRCCS, Department of Cardiovascular Medicine, Università Cattolica del Sacro Cuore, Rome, ItalyInternational University of Health and Welfare, Narita, JapanCalcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standard treatments, several other alternative drugs and interventions have been proposed, including the Rho-kinase inhibitor fasudil, anti-adrenergic drugs, neural therapies and percutaneous coronary interventions. In patients with syncope or cardiac arrest caused by CAS-related tachyarrhythmias, or even bradyarrhythmias, implantation of an ICD or pacemaker, respectively, should be considered according to the risk of recurrence and efficacy of vasodilator therapy.https://www.ecrjournal.com/articleindex/ecr.2022.47 |
| spellingShingle | Gaetano Antonio Lanza Hiroaki Shimokawa Management of Coronary Artery Spasm European Cardiology Review |
| title | Management of Coronary Artery Spasm |
| title_full | Management of Coronary Artery Spasm |
| title_fullStr | Management of Coronary Artery Spasm |
| title_full_unstemmed | Management of Coronary Artery Spasm |
| title_short | Management of Coronary Artery Spasm |
| title_sort | management of coronary artery spasm |
| url | https://www.ecrjournal.com/articleindex/ecr.2022.47 |
| work_keys_str_mv | AT gaetanoantoniolanza managementofcoronaryarteryspasm AT hiroakishimokawa managementofcoronaryarteryspasm |